AstraZeneca Acknowledges Rare Thrombosis Risk in Covishield COVID-19 Vaccine
![AstraZeneca Acknowledges Rare Thrombosis Risk in Covishield COVID-19 Vaccine](/uploads/2024/04/astrazeneca-acknowledges-rare-thrombosis-risk-in-covishield-covid-19-vaccine.webp)
AstraZeneca has officially confirmed that its COVID-19 vaccine, Covishield, could lead to a rare condition known as Thrombosis with Thrombocytopenia Syndrome (TTS). Developed with the Serum Institute of India, Covishield's potential side effects have raised concerns across India.
Continue Reading